Quality of Life in IBS Patients Treated With Mebeverine Hydrochloride or Pinaverium Bromide–Results of an International Prospective Observational Cohort Study in Poland, Egypt, Mexico, and China

Abstract

Background and AimsInflammatory bowel disease (IBS) has a substantial impact on health-related quality of life (HR QoL). As there are limited data available post-treatment, specifically with mebeverine hydrochloride and pinaverium bromide, this study was initiated in different regions of the world among patients receiving these treatments to evaluate the quality of life (QoL) data. This study aimed to evaluate the changes from baseline in the IBS QoL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide.MethodsThis was a prospective observational ort study in patients with IBS, diagnosed using the ROME III criteria in 4 countries (Poland, Egypt, Mexico and China).ResultsA total of 607 patients were enrolled. At baseline, the IBS QoL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China, and 56.4 overall. Increases in IBS QoL total score were statistically significant at 4 and 8 weeks, overall and in each country (overall: 11.8 at week 4, 24.3 at week 8; P < .001 for all comparisons) (Figure 1). Increases were shown in all IBS QoL sub scores. Symptoms and health economic outcomes were improved. Furthermore, the favorable safety profile of these treatments was confirmed.Conclusions Background and AimsInflammatory bowel disease (IBS) has a substantial impact on health-related quality of life (HR QoL). As there are limited data available post-treatment, specifically with mebeverine hydrochloride and pinaverium bromide, this study was initiated in different regions of the world among patients receiving these treatments to evaluate the quality of life (QoL) data. This study aimed to evaluate the changes from baseline in the IBS QoL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide. Inflammatory bowel disease (IBS) has a substantial impact on health-related quality of life (HR QoL). As there are limited data available post-treatment, specifically with mebeverine hydrochloride and pinaverium bromide, this study was initiated in different regions of the world among patients receiving these treatments to evaluate the quality of life (QoL) data. This study aimed to evaluate the changes from baseline in the IBS QoL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide. MethodsThis was a prospective observational ort study in patients with IBS, diagnosed using the ROME III criteria in 4 countries (Poland, Egypt, Mexico and China). This was a prospective observational ort study in patients with IBS, diagnosed using the ROME III criteria in 4 countries (Poland, Egypt, Mexico and China). ResultsA total of 607 patients were enrolled. At baseline, the IBS QoL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China, and 56.4 overall. Increases in IBS QoL total score were statistically significant at 4 and 8 weeks, overall and in each country (overall: 11.8 at week 4, 24.3 at week 8; P < .001 for all comparisons) (Figure 1). Increases were shown in all IBS QoL sub scores. Symptoms and health economic outcomes were improved. Furthermore, the favorable safety profile of these treatments was confirmed. A total of 607 patients were enrolled. At baseline, the IBS QoL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China, and 56.4 overall. Increases in IBS QoL total score were statistically significant at 4 and 8 weeks, overall and in each country (overall: 11.8 at week 4, 24.3 at week 8; P < .001 for all comparisons) (Figure 1). Increases were shown in all IBS QoL sub scores. Symptoms and health economic outcomes were improved. Furthermore, the favorable safety profile of these treatments was confirmed. Conclusions